Literature DB >> 8396851

Interleukin-8 production by the human cervix.

C G Barclay1, J E Brennand, R W Kelly, A A Calder.   

Abstract

OBJECTIVES: Our purpose was (1) to determine whether the human cervix is capable of producing interleukin-8 in vitro and to examine the possibility of stimulating an increase in any such output and (2) to examine the concomitant production of prostaglandins. STUDY
DESIGN: Cervical tissue was obtained from 48 women, 29 pregnant women undergoing surgical termination of pregnancy (20 of whom were treated with the prostaglandin analog Cervagem), 14 nonpregnant, premenopausal women, and three postmenopausal women. Explants were cultured and the medium was assayed for interleukin-8 and prostaglandin E2. Analysis of variance and Newman-Keuls statistical tests were used.
RESULTS: Significant quantities of interleukin-8 were produced by the tissue, and the data indicate that cervical explants from pregnant and nonpregnant women behave in a similar way when challenged by phorbol myristate acetate but that the postmenopausal cervix loses its capacity for interleukin-8 production.
CONCLUSIONS: Human cervix is capable of producing large amounts of interleukin-8 in vitro, and it may be influenced by the steroid hormones. Thus interleukin-8 could be an excellent candidate for a prime role in neutrophil-mediated cervical ripening.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396851     DOI: 10.1016/0002-9378(93)90634-u

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

Review 1.  Management of preterm labour.

Authors:  S Vause; T Johnston
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 2.  The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified?

Authors:  Roberto Romero; Jimmy Espinoza; Offer Erez; Sonia Hassan
Journal:  Am J Obstet Gynecol       Date:  2006-01       Impact factor: 8.661

Review 3.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

4.  Decreased type III collagen expression in human uterine cervix of prolapse uteri.

Authors:  Masaaki Iwahashi; Yasuteru Muragaki
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

5.  Glucocorticoid-independent repression of tumor necrosis factor (TNF) alpha-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response.

Authors:  Nicolette J D Verhoog; Andrea Du Toit; Chanel Avenant; Janet P Hapgood
Journal:  J Biol Chem       Date:  2011-04-07       Impact factor: 5.157

6.  Estrogen and progesterone metabolism in the cervix during pregnancy and parturition.

Authors:  Stefan Andersson; Debra Minjarez; Nicole P Yost; R Ann Word
Journal:  J Clin Endocrinol Metab       Date:  2008-03-25       Impact factor: 5.958

7.  Interleukin-1beta induces glycosaminoglycan synthesis via the prostaglandin E2 pathway in cultured human cervical fibroblasts.

Authors:  T Schmitz; M J Leroy; E Dallot; M Breuiller-Fouche; F Ferre; D Cabrol
Journal:  Mol Hum Reprod       Date:  2003-01       Impact factor: 4.025

8.  Transcriptomic profile of VEGF-regulated genes in human cervical epithelia.

Authors:  MacKinsey Johnson; Chishimba Nathan Mowa
Journal:  Cell Tissue Res       Date:  2021-01-29       Impact factor: 5.249

9.  Leukocytes are primed in peripheral blood for activation during term and preterm labour.

Authors:  M Yuan; F Jordan; I B McInnes; M M Harnett; J E Norman
Journal:  Mol Hum Reprod       Date:  2009-07-23       Impact factor: 4.025

10.  Delineation of VEGF-regulated genes and functions in the cervix of pregnant rodents by DNA microarray analysis.

Authors:  Chishimba N Mowa; Tianbo Li; Subrina Jesmin; Hans G Folkesson; Sharon E Usip; Raymond E Papka; Guichuan Hou
Journal:  Reprod Biol Endocrinol       Date:  2008-12-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.